Skip to content

Author

E. Flanagan

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Normal pressure hydrocephalus in people with multiple sclerosis.

BACKGROUND Aging people with multiple sclerosis (pwMS) may develop idiopathic normal pressure hydrocephalus (INPH). OBJECTIVES Describe clinical, investigational, and treatment courses in pwMS and INPH. METHODS Retrospective Mayo Clinic database review of "MS" and "NPH" and "Gait disorder" 1996-2025. INCLUSION CR...

Purna Chowdhury, J. Cutsforth-Gregory, David T. Jones et al. · 0 citations
Review Sep 2026

The pooled prevalence of cognitive impairment in adults with myelin oligodendrocyte glycoprotein antibody-associated disease: A Systematic Review & Meta-Analysis.

OBJECTIVE To determine the pooled prevalence of cognitive impairment (CI) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) relative to relapsing-remitting multiple sclerosis (RRMS) and identify the primary cognitive domains impaired. METHODS Electronic databases were searched from inception...

A. Aboseif, Karlo Toljan, Moritz A. Niederschweiberer et al. · 0 citations
Review Sep 2026

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review.

Importance Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...

E. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al. · 0 citations
Review Open access Aug 2026

Application of the 2024 McDonald Criteria

This review contextualizes the implications of key revisions in the 2024 McDonald criteria for routine clinical care, while providing accessible guidance for its appropriate application with a lens toward nonspecialist clinicians and trainees globally, to ensure early and accurate MS diagnosis.

A. J. Solomon, W. Brownlee, Shanthi Viswanathan et al. · 0 citations
Review Open access Aug 2026

De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD

Treatment de-escalation is sometimes necessary because of adverse effects, comorbidities, infections, treatment fatigue, or life circumstances such as pregnancy, but in pregnancy, management requires balancing maternal disease control with fetal safety, with strategies ranging from continuation of selected therapies to...

Y. Hacohen, G. Androdias, G. Arrambide et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.